Fatty‑liver numbers set to explode

Fatty liver disease is on track to affect about 1.8 billion people worldwide by 2050, according to a review published in 2026. (ajmc.com) Doctors now call the condition metabolic dysfunction-associated steatotic liver disease, or MASLD. The American Association for the Study of Liver Diseases says the new name replaced nonalcoholic fatty liver disease in June 2023 and covers people with fat in the liver plus at least one cardiometabolic risk factor. (aasld.org) In plain terms, MASLD means fat builds up in the liver in people who often also have obesity, type 2 diabetes, or metabolic syndrome. The National Institute of Diabetes and Digestive and Kidney Diseases says the disease is usually silent at first and can progress from simple fat buildup to inflammation and liver damage. (niddk.nih.gov) The review cited by The American Journal of Managed Care estimated global prevalence at 16.1% in 2023. On current trends, that would climb to roughly 1.8 billion cases by 2050. (ajmc.com) Those trends line up with the broader rise in body weight worldwide. The World Health Organization said 2.5 billion adults were overweight in 2022, including 890 million living with obesity. (who.int) Liver specialists describe MASLD as more than a liver problem. A 2025 review in The New England Journal of Medicine and a cardiology review indexed by PubMed both describe it as a multisystem disease closely tied to cardiovascular disease, which is the leading cause of death in this population. (pubmed.ncbi.nlm.nih.gov 1) (pubmed.ncbi.nlm.nih.gov 2) The sickest subgroup is called metabolic dysfunction-associated steatohepatitis, or MASH, which means fat buildup has advanced to inflammation and cell injury. The liver society says MASH is the replacement term for nonalcoholic steatohepatitis, while the federal liver institute says inflammation and fibrosis can improve with weight loss. (aasld.org) (niddk.nih.gov) Treatment is starting to change, but only for a slice of patients. The Food and Drug Administration approved Rezdiffra, or resmetirom, in March 2024 for adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced fibrosis, alongside diet and exercise. (fda.gov) Even with that approval, the main tools remain screening people at risk, managing diabetes and obesity, cutting alcohol that can worsen disease, and preventing scarring before cirrhosis develops. The liver society says resmetirom is the only current Food and Drug Administration-approved therapy, and its use is limited to a narrower group than the billions projected to have MASLD. (aasld.org) (fda.gov) The numbers in the new review point to a disease that often goes unnoticed until damage is harder to reverse. By 2050, the biggest strain may come not from rare liver disorders, but from a common one tied to everyday diet, weight, blood sugar, and alcohol use. (ajmc.com) (niddk.nih.gov)